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Background. Roux-en-Y gastric bypass (RYGBP) is an established method for treatment of obesity, a condition of chronic
inﬂammation with liver steatosis, characterised by increased erythrocyte sedimentation rate (ESR), white blood cell count (WBC),
liver enzymes, and decreased magnesium (Mg). We investigated alterations, if any, in ESR, WBC, alanine aminotransferase (ALT),
gamma-glutamyl transferase (GGT), and Mg after RYGBP. Methods. 21 morbidly obese nondiabetic patients who underwent
RYGBP surgery were evaluated preoperatively (baseline), then 1 year (1st followup) and 3.5 years (2nd followup) after RYGBP
and compared to an untreated control group. Results. Body mass index, ESR, WBC, ALT, and GGT were all signiﬁcantly reduced
at 1 year in the RYGBP group (30%, 35%, 20%, 45%, and 57%, resp.) while Mg increased by 6%, compared to control group
(P = 0.001 − 0.009). Conclusions. Obese patients treated by RYGBP show sustained reductions in ESR, WBC, ALT, and GGT
possibly due to reduced liver steatosis and increased Mg.
1.Introduction
Bariatric surgery has become an eﬀective treatment for obe-
sity, also improving glucose tolerance, insulin sensitivity, lip-
id status [1–3], and reducing mortality [4, 5].
Obesity is a chronic condition [6, 7] characterised by ele-
v a t e di n ﬂ a m m a t o r ym a r k e r ss u c ha se r y t h r o c y t es e d i m e n t a -
tionrate(ESR),c-reactiveprotein(CRP),ﬁbrinogenconcen-
trations,andincreasedwhitebloodcell(WBC)count[8–10].
Furthermore, these markers are correlated with central dis-
tribution of body fat, high blood pressure, hyperglycemia,
dyslipidemia, and hyperinsulinemia, all well-known risk fac-
tors for cardiovascular disease [11, 12]. ESR, which measures
the tendency of red blood cells to aggregate, has been iden-
tiﬁed as an independent predictor for myocardial infarction
[13, 14] and coronary heart disease (CHD) [15, 16]. WBC
hasalsobeenshowntopredictCHD[17–19].Bariatricsurgi-
cal procedure such as adjustable gastric banding and RYGBP
is associated with lowered WBC [20–23]. Corresponding in-
formation on ESR changes after RYGBP is scant.
Obesity is also associated with nonalcoholic fatty liver
disease (NAFLD) [24, 25]. Serum alanine aminotransferase
(ALT) and serum gamma-glutamyltransferase (GGT) are
m a r k e r so fN A F L Da n do fl i v e rf a tc o n t e n t[ 26, 27]a n d
are found to predict the onset of type 2 diabetes mellitus
(T2DM) [28]a sw e l la sC H D[ 29–31]. Dysmetabolic condi-
tions like obesity and nonalcoholic steatohepatitis have also
been associated with a low magnesium (Mg) status [32, 33].
Theaimofthisstudywastoassesschanges,ifany,inmor-
bidlyobesepatientstreatedwithRYGBP(n = 21)after1year
and after 3.5 years after surgery, regarding ESR, WBC, serum
concentrations of ALT, GGT, Mg, and creatinine in compar-
ison with a morbidly obese untreated control group.
2.MaterialandMethods
2.1. Patients. Twenty-one consecutive patients (three male,
eighteen female), all Caucasians, with morbid obesity, with-
out established diabetes, and on the waiting list for RYGBP2 Journal of Obesity
Table 1: Clinical characteristics for patients before RYGBP surgery and at followups 1 year and 3.5 years after surgery and for morbidly
obese controls at baseline.
Controls
baseline
RYGBP
baseline
RYGBP
1 year
RYGBP
3.5 years
P for
diﬀerence at
baseline
P for trend
RYGBP
Gender (women/men) 16/5 18/3 18/3 18/3 0.429 —
Age (years) 38.7 (7.5) 45.7 (9.7) — — 0.013 —
BMI (kg/m2) 44.3 (5.1) 42.3 (5.2) 29.7 (4.6) 32.1 (5.3) 0.211 <0.001
Weight (kg) 124.0 (17.3) 120.0 (16.4) 84.0 (13.6) 90.8 (16.0) 0.444 <0.001
Height (cm) 167.2 (8.5) 168.4 (6.2) — — 0.614 —
ESR (mm/hr) 16 (10) 17 (7) 11 (7) 12 (8) 0.679 0.018
White blood cell count
(×109/L) 7.5 (1.6) 7.0 (1.53) 5.6 (1.04) 6.0 (1.55) 0.300 0.006
S-ALT (µkatal/L) 0.57 (0.48) 0.62 (0.25) 0.34 (0.18) 0.24 (0.10) 0.691 <0.001
S-GGT (µkatal/L) 0.69 (0.46) 0.65 (0.42) 0.28 (0.19) 0.31 (0.24) 0.815 <0.001
S-magnesium (mmol/L) 0.80 (0.06) 0.80 (0.06) 0.85 (0.08) 0.87 (0.07) 0.961 0.009
S-creatinine (mmol/L) 81.8 (10.1) 75.9 (8.7) 75.3 (8.3) 73.6 (9.8) 0.051 0.704
Data given are arithmetic means (±SD).
BMI: body mass index, ESR: erythrocyte sedimentation rate, ALT: alanine aminotransferase, GGT: gamma-glutamyl transferase, S: serum.
were recruited from the Outpatient Clinic of Obesity Care,
Uppsala University Hospital, Uppsala, Sweden.
Patients were investigated preoperatively (baseline), and
then 1 year (1st followup) and 3.5 years (2nd followup)
after RYGBP. Data from the RYGBP group were compared
to that of a baseline matched morbidly obese control (MOC)
group also recruited from the waiting list for RYGBP. Thus,
this MOC group showed similar characteristics as compared
to the RYGBP group; however, since the control group was
recruited from the waiting list it was not possible to follow
up longer than one year. The MOC group consisted of 21
morbidly obese patients (5 men, 16 women) who also did
not have established diabetes and without pharmacological
treatmentfordiabetes.Baselinecharacteristicsofthesubjects
are shown in Table 1.
Exclusion criteria for participation were anaemia, liver
disease, high alcohol consumption (>21 units per week, 1
unit = 8g alcohol), use of hypoglycaemic agents, or lipid-
lowering medication at baseline or followups.
The study was approved by the regional ethics review
board at Uppsala University.
2.2.RYGBPSurgeryProcedure. RYGBPexcludedthestomach
and duodenum from the passage of food. The ﬂaccid part
of the lesser omentum and the ﬁrst gastric vessel on the
lesser curvature was divided just below the fat pad, to create
a small gastric pouch (2cm by 3cm). The pouch was then
totally separated from the main stomach, which was left in
the abdomen. The small bowel was divided 30cm distal to
the ligament of Treitz, and the aboral end was connected to
the small gastric pouch. This jejunal limb, the so-called Roux
limb, was made 70cm long and placed behind the excluded
stomach and transverse colon. The small bowel continuity
was maintained by an enteroenterostomy between the Roux
limb and the earlier divided proximal jejunum. This created
theY-shapedjunctionwheretheingestedfood,viatheRoux-
limb, and the gastric acid and bile are mixed.
All participants were given the same kind of dietary ad-
vice after surgery and were recommended to take a daily oral
supplement containing vitamins and minerals (Vitamineral)
which does not contain magnesium.
2.3. Test Procedures. All participants underwent physical ex-
aminationandbloodtestsforESR,WBC,ALT,GGT,Mg,and
creatinine preoperatively (baseline) and at 1st and 2nd fol-
lowups. Blood samples were collected from each patient fol-
lowing an overnight fast and analysed.
2.4. Clinical Measurements. Weight (kg) and height (m)
were measured on standardised calibrated scales, and BMI
(kg/m2) was calculated.
2.5. Laboratory Analyses. Serum concentrations of ALT,
GGT, and creatinine were analyzed using routine meth-
ods for clinical chemistry at the Department of Clinical
Chemistry at the University Hospital, Uppsala. Plasma
ESR level (mm/hr) was assessed by Sedimatic 100 (Guest
Scientiﬁc A.G., Cham, Switzerland). WBC was measured
by a Cell-Dyn Sapphire (Abbott, Santa Clara, USA). Serum
Mg was measured by spectrophotometric determination as
previously reported [34].
2.6. Statistics. A l la n a l y s e sw e r ed e ﬁ n e dap r i o r i .R e s u l t s
are given as arithmetic mean with their standard deviation.
ANOVA was used for trends over three and half years
of followup. Changes between diﬀerent time points were
analysed using paired t-test. Tests were two-tailed, and a P
value <0.05 was considered signiﬁcant. Statistical software
JMP 3.2 forPC (SAS Corporation, Cary, Tex, USA) was used.
3. Results
3.1. Baseline Data. Clinical characteristics for patients at
baseline, that is, before RYGBP surgery, are shown in Table 1.Journal of Obesity 3
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Figure1:Thechangesinerythrocytesedimentationrate(ESR)(a),whitebloodcell(WBC)count(b),serumalanineaminotransferase(ALT)
(c), and gamma-glutamyl transferase (GGT) (d) concentrations are shown at baseline and at 1st followup (1 year) and 2nd followup (3.5
years) after Roux-en-Y gastric bypass surgery. Mean values are shown. Statistical signiﬁcance indicated by P values. F-up denotes followup.
There were no statistically signiﬁcant diﬀerences in gender,
mean BMI, ESR, WBC, or serum concentrations of ALT,
GGT, and Mg in the RYGBP group compared with MOC
group. Mean age in the MOC group was lower.
3.2.Follow-UpDataat1Year(1stFollowup,RYGBPandMOC
Groups) and 3.5 Years (2nd Followup, RYGBP Group). BMI,
ALT, GGT, ESR, and WBC were all decreased over the three
and half years of followup after RYGBP while Mg was found
to increase.
BMI was reduced by 30% in the RYGBP group, from
42.3kg/m2 at baseline to 29.7kg/m2 at 1st followup (P<
0.001), and by 24%, from 42.3kg/m2 to 32.1kg/m2 at 2nd
followup (P<0.001) implying a 6% gain (gain over the bas-
eline BMI) between 1st and 2nd followups (P<0.001). In
the MOC group BMI was unaltered between baseline and 1st
followup (44.3 and 44.2kg/m2,r e s p . ;P = 0.920). At 1st fol-
lowup, the intergroup diﬀerence (between the RYGBP and
MOC groups) was signiﬁcant (P<0.001).
ESR decreased by 35% in the RYGBP group, from
17mm/hr at baseline to 11mm/hr at 1st followup (P =
0.001) and to 12mm/hr at 2nd followup (P = 0.018)
with no signiﬁcant change between 1st and 2nd followups
(P = 0.333) (Figure 1(a)). In the MOC group, ESR was un-
changed,16mm/hratbothoccasions(P = 0.567).Theinter-
group diﬀerence at 1st followup was signiﬁcant (P<0.001).
WBC decreased by 20% in the RYGBP group, from 7.0
× 109/L at baseline to 5.6 × 109/L at 1st followup (P =
0.001) and to 6.0 × 109/L at 2nd followup (P = 0.007)
with no signiﬁcant change between 1st and 2nd followups
(P = 0.230) (Figure 1(b)). In the MOC group no change
in WBC was observed between baseline and 1st followup
(7.5 and 8.3 × 109/L, resp.; P = 0.0734). The intergroup
diﬀerence at 1st followup was signiﬁcant (P<0.001).
ALT was markedly lowered by 45% in the RYGBP group,
from 0.62µkatal/L at baseline to 0.34µkatal/L at 1st followup
and to 0.24µkatal/L at 2nd followup (both P<0.001). The
further decrease of 29%, between 1st and 2nd followups,
was also signiﬁcant (P = 0.02) (Figure 1(c)). In the MOC
group, ALT was unchanged, 0.57µkatal/L at both occasions
(P = 0.842). The intergroup diﬀerence at 1st followup was
signiﬁcant (P = 0.001).
GGT was also markedly lowered by 57% in the RYGBP
group, from 0.65µkatal/L at baseline to 0.28µkatal/L at 1st4 Journal of Obesity
followup (P<0.001) and to 0.31 µkatal/L at 2nd followup
(both P<0.001) with no signiﬁcant change between 1st and
2nd followups (P = 0.408) (Figure 1(d)). In the MOC group
an opposite trend was observed between baseline and 1st fol-
lowup (0.69 and 0.81µkatal/L, resp.; P = 0.086). The inter-
group diﬀerence at 1st followup was signiﬁcant (P<0.001).
Mg increased by 6% in the RYGBP group, from
0.80mmol/L at baseline to 0.85mmol/L at 1st followup (P =
0.009) and further to 0.87mmol/L at 2nd followup (P<
0.001); however, the change between 1st and 2nd followups
(P = 0.133) was not signiﬁcant. In the MOC group no
changewasobservedbetweenbaselineand1stfollowup(0.80
and 0.77mmol/L, resp.; P = 0.132); however, the intergroup
diﬀerence at 1st followup was signiﬁcant (P<0.014).
No changes in creatinine levels were observed in the
RYGBP group or in the MOC group.
3.3. Pearson’s Product-Moment Correlation Coeﬃcients. A
higherbaselineBMIcorrelatedwithincreasedESR(r = 0.41,
P = 0.012) and with decreased Mg (r =− 0.30, P = 0.03)
but not signiﬁcantly with WBC (r =− 0.16, P = 0.303), ALT
(r = 0.176, P = 0.269), or GGT (r =− 0.02, P = 0.198).
4. Discussion
The main ﬁndings in this study were that ESR, WBC, and
liver enzymes, ALT and GGT, decreased after RYGBP sur-
gery. The sustained lowering of ESR and WBC, markers
of inﬂammation, may indicate a long-term improvement
regarding inﬂammatory status in obese subjects treated by
RYGBP surgery along with a sustained lowering of both
ALT and GGT, markers for liver steatosis and for metabolic
and cardiovascular risk [30, 31]. Obesity is an inﬂammatory
condition [6, 7] associated with elevated inﬂammatory
markers such as ESR, CRP, ﬁbrinogen, and WBC [8–10,
35]. It has been shown that CRP and other inﬂammatory
biomarkers predict cardiovascular mortality [36]. Lowered
CRP and WBC concentrations have been reported with
at least 1 year’s followup after RYGBP as well as after
gastricbanding[20].DecreasedESRlevelswerealsoreported
one and four years after gastric banding [21, 23]. RYGBP
induces a larger weight loss than gastric banding, but data
on ESR after RYGBP has been less complete. ESR has less
intraindividual variation than CRP, which is inﬂuenced by
minor infections, for example, common cold, and also by
degree of physical activity. Our results show a decrease in
ESR by 35% one year after RYGBP surgery which was sus-
tained over time up to 3.5 years of followup. In contrast, no
diﬀerence was observed in the control group.
In this study ESR was measured according to the prin-
ciples of the F˚ ahræus-Westergren method [37, 38]w h i c hi s
considered the gold standard for determination of erythro-
cyte sedimentation rate. ESR is a widely available test and is
used as a nonspeciﬁc marker of inﬂammation. It is higher
in obesity and increases with age. The ESR value depends on
the balance between factors promoting and factors resisting
erythrocyte sedimentation. The promoting factors include
ﬁbrinogen (an acute-phase protein) and other proinﬂamma-
torycytokines.Levelsofﬁbrinogenandtheproinﬂammatory
cytokines are elevated in inﬂammatory conditions, their
production by the hepatocytes being increased [39].
Hepatocyteproductionoftheseacute-phaseproteinsisin
turn inﬂuenced by the degree of liver steatosis [40, 41]. Non-
alcoholic fatty liver disease (NAFLD), of which liver steatosis
ispart,occursinobesityandisassociatedwithelevatedﬁbro-
gen and liver enzymes [40, 42, 43]. Lowered liver enzymes
suchasGGThavebeenreportedtopredicttheimprovements
in inﬂammation and ﬁbrosis in the hepatocytes in NAFLD,
two key prognostic features of this condition [27]. The low-
ered serum GGT, ALT, and ESR observed in this study after
RYGBP might thus reﬂect decreased degree of liver steatosis.
A similar pattern regarding ﬁbrinogen, ALT, and GGT
has previously been shown after gastric banding [23, 27].
Thus, it might be speculated that in the present study a de-
creased liver steatosis after RYGBP surgery has contributed
to a reduced ﬁbrinogen synthesis and lowered ESR.
WBC is increased in inﬂammatory conditions and is in-
creasedinobesityandcorrelateswithcentralobesity[44,45].
It is also associated with NAFLD regardless of the presence of
classical cardiovascular risk factors and other components of
metabolic syndrome [46]. The present study showed a de-
crease in WBC by 20% three and a half years after RYGBP
which is in congruence with other shorter studies [20, 22].
Our results indicate that the lowered WBC may be sustained
in the long term.
This study conﬁrmed the ﬁndings from a previous study
that noted increase in serum Mg one year after RYGBP [34]
and further documented sustenance of this increase up to
three and a half years. This increase is not thought to be due
to impaired renal function as the serum creatinine did not
change in the follow-up interval. The exact mechanisms have
still to be explained.
Possible limitations to the study would be that the pres-
ence of concomitant minor infections was not documented.
However, anaemia and renal impairment, factors which
might inﬂuence ESR, were not observed in our study. We
did not measure CRP for direct comparison with ESR. The
control group was signiﬁcantly younger than the RYGBP
group, but since ESR increases with age it is unlikely that this
had an inﬂuence on the ESR results. Body fat content and
liver fat content measured by imaging techniques like Dual
energyX-rayabsorptiometryorultrasonographywouldhave
been warranted to investigate if diﬀerent fat distribution
might inﬂuence the variables analysed in this study.
In conclusion, morbidly obese patients treated with
RYGBP show a marked and sustained decrease in ESR, WBC,
ALT, and GGT which may indicate improvements in general
inﬂammatory status and particularly steatohepatitis. They
also show sustained increases in Mg.
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